Form 4: NewAmsterdam Pharma CEO Davidson Reports Share Transactions

NewAmsterdam Pharma CEO Michael H. Davidson reported the sale of shares to cover tax obligations and the acquisition of new restricted stock units and stock options.

Summary

• CEO Michael H. Davidson engaged in multiple transactions on January 7, 2026, under a Rule 10b5-1(c) plan.
• Sold 11,582 ordinary shares at a weighted average price between $35.24 and $35.59 per share. This sale was solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) and was not a discretionary transaction.
• Acquired 81,000 ordinary shares through the vesting and settlement of RSUs. These RSUs will vest 1/3 on each of the first, second, and third anniversaries of the vesting start date (January 7, 2026), contingent on continued service.
• Acquired 364,000 options to buy ordinary shares at an exercise price of $35.45 per share. These options will vest 25% on January 2, 2027, with the remaining shares vesting in equal monthly installments thereafter for three years, also contingent on continued service.
• Following these reported transactions, Davidson directly beneficially owns 459,859 ordinary shares and 364,000 options.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation and tax-related transactions. The grant of new equity incentives is generally positive for aligning management with shareholder interests, while the sale is non-discretionary and for tax purposes.

Positives

• The grant of 81,000 Restricted Stock Units (RSUs) and 364,000 stock options aligns management's interests with long-term shareholder value creation.
• The transactions were pre-arranged under a Rule 10b5-1(c) plan, indicating planned and non-discretionary sales for tax purposes.

Negatives

• The sale of 11,582 ordinary shares, even for tax purposes, results in a reduction of direct share ownership by the CEO.

Risks

• Future share price fluctuations could impact the ultimate value realized from the options and RSUs.
• Continued service through the specified vesting dates is required for the RSUs and options to fully vest, posing a risk to the reporting person if employment ceases.

Future Outlook

The vesting schedules for the newly acquired RSUs and stock options extend over several years, indicating a long-term incentive structure for the CEO, contingent on continued service and designed to align executive interests with long-term company performance.

Management Comments

• The sale does not represent a discretionary transaction by the Reporting Person.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Industry Context

This filing reflects standard executive compensation practices in the biotechnology and pharmaceutical industry, where long-term incentives like RSUs and stock options are commonly used to align executive performance with shareholder interests. The 'sell-to-cover' mechanism for tax obligations is also a routine practice for equity compensation.

Comparison to Industry Standards

• The use of RSUs and stock options as a significant component of executive compensation is a common practice across the pharmaceutical and biotech sectors, comparable to companies like Moderna, Pfizer, or BioNTech, which also utilize equity-based incentives to retain talent and motivate long-term performance.
• The vesting schedules, typically 3-4 years for RSUs and options, are standard for executive grants, similar to those observed at peer companies such as Regeneron Pharmaceuticals or Vertex Pharmaceuticals, ensuring sustained commitment from leadership.
• The 'sell-to-cover' transaction for tax withholding is a widely accepted and non-discretionary method for executives to manage tax liabilities upon equity vesting, consistent with practices seen at numerous public companies across all industries.

Stakeholder Impact

• Shareholders: The grant of long-term equity incentives to the CEO aligns his interests with long-term shareholder value creation. The small 'sell-to-cover' sale has minimal impact on overall share float.
• Employees: No direct impact mentioned for general employees.

Next Steps

• Continued vesting of 81,000 RSUs on the first, second, and third anniversaries of January 7, 2026.
• Continued vesting of 364,000 stock options, with 25% vesting on January 2, 2027, and the remainder monthly over three years.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related share sales under a pre-arranged plan. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant of new equity incentives is a standard practice to align management with long-term shareholder interests, reinforcing a 'hold' stance for investors awaiting further operational updates.

Keywords

NewAmsterdam Pharma, NAMS, SEC Form 4, Insider Trading, Executive Compensation, Stock Options, RSUs, Michael H. Davidson, Share Sale, Tax Withholding